Article
Myeloid cell path to malignancy: insights into liver cancer
26 Mar 2025
Abstract excerpt
Clinically approved treatments for advanced liver cancer often lack potency because of the heterogeneous characteristics of hepatocellular carcinoma (HCC). This complexity is largely driven by context-dependent inflammatory responses brought on by diverse etiologies, such as metabolic dysfunction-associated steatohepatitis (MASH), the genetic makeup of cancer cells, and the versatile adaptability of immune cells,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
